Lead Product(s): Paxalisib
Therapeutic Area: Oncology
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2020
Interim analysis of Part showed median overall survival of 17.7 months, representing a clinically meaningful extension of life when compared to the 12.7 months of temozolomide.